These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38951682)
1. The renin-angiotensin-aldosterone system inhibitor dilemma in COVID-19: balancing cardiovascular benefits and viral risks. Okumura T; Murohara T Hypertens Res; 2024 Sep; 47(9):2598-2600. PubMed ID: 38951682 [No Abstract] [Full Text] [Related]
2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update. Shukla AK; Banerjee M High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis. Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399 [No Abstract] [Full Text] [Related]
4. SARS-CoV-2 effects on the renin-angiotensin-aldosterone system, therapeutic implications. Ye Q; Lai EY; Luft FC; Persson PB; Mao J Acta Physiol (Oxf); 2021 Apr; 231(4):e13608. PubMed ID: 33350096 [No Abstract] [Full Text] [Related]
5. Drugs and the renin-angiotensin system in covid-19. Aronson JK; Ferner RE BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880 [No Abstract] [Full Text] [Related]
6. The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients. Harky A; Chor CYT; Nixon H; Jeilani M J Renin Angiotensin Aldosterone Syst; 2021; 22(1):1470320320987118. PubMed ID: 33412991 [No Abstract] [Full Text] [Related]
7. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial. Mancia G Cardiovasc Res; 2020 Dec; 116(14):e198-e199. PubMed ID: 33245754 [No Abstract] [Full Text] [Related]
8. COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved? Tadic M; Cuspidi C J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1984-1986. PubMed ID: 32951351 [No Abstract] [Full Text] [Related]
9. [Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers]. Mareev YV; Mareev VY Kardiologiia; 2020 Apr; 60(4):4-9. PubMed ID: 32394850 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore. Saavedra JM Physiology (Bethesda); 2021 May; 36(3):160-173. PubMed ID: 33904788 [TBL] [Abstract][Full Text] [Related]
11. Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research. Loader J; Taylor FC; Lampa E; Sundström J J Am Heart Assoc; 2022 Jun; 11(11):e025289. PubMed ID: 35624081 [TBL] [Abstract][Full Text] [Related]
12. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis. Guo X; Zhu Y; Hong Y Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694 [No Abstract] [Full Text] [Related]
13. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760 [No Abstract] [Full Text] [Related]
14. COVID-19 and inhibitors of the renin-angiotensin-aldosterone system. Hussain M; Jabeen Q; Ahmad FU; Kashif-Ur-Rehman ; Fatima M; Shaukat S; Majeed A; Barkat MQ; Wu X Expert Rev Anti Infect Ther; 2021 Jul; 19(7):815-816. PubMed ID: 33198546 [No Abstract] [Full Text] [Related]
15. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Singh AK; Gupta R; Misra A Diabetes Metab Syndr; 2020; 14(4):283-287. PubMed ID: 32283499 [TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients. Ateya AM; Sabri NA J Med Virol; 2021 Apr; 93(4):1873-1874. PubMed ID: 33200431 [No Abstract] [Full Text] [Related]
17. The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic. Augoustides JGT J Cardiothorac Vasc Anesth; 2020 Jul; 34(7):1717-1719. PubMed ID: 32360010 [No Abstract] [Full Text] [Related]
18. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension. Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731 [TBL] [Abstract][Full Text] [Related]
19. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. Vila-Corcoles A; Satue-Gracia E; Ochoa-Gondar O; Torrente-Fraga C; Gomez-Bertomeu F; Vila-Rovira A; Hospital-Guardiola I; de Diego-Cabanes C; Bejarano-Romero F; Rovira-Veciana D; Basora-Gallisa J J Clin Hypertens (Greenwich); 2020 Aug; 22(8):1379-1388. PubMed ID: 32710674 [TBL] [Abstract][Full Text] [Related]
20. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]